List view / Grid view
Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it is a 2011 winner of Microsoft Corporation’s Life Sciences Innovation Awards. This is the fourth consecutive year that the company has been recognized by Microsoft, demonstrating Thermo Fisher’s leading position as a provider of innovative enterprise…
30 June 2011 | By Novartis
Results from the pivotal Phase III GLOW2 clinical trial show that once-daily NVA237, 50 mcg significantly improved lung function...
29 June 2011 | By Pfizer
Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio...
29 June 2011 | By AstraZeneca
AstraZeneca & PTC have entered into an exclusive research collaboration & license agreement...
29 June 2011 | By kdm communications limited
Tecan announced that entries are now open for the 2011 Tecan Award. The Tecan Award is designed to celebrate the innovation and ingenuity of Tecan’s loyal customers...
29 June 2011 | By Macmillan Cancer Support
Mike Hobday, Head of Policy at Macmillan Cancer Support, said...
28 June 2011 | By Pfizer
The U.S. FDA has accepted Pfizer’s filing for standard review of axitinib for patients with advanced RCC...
28 June 2011 | By Merck
UPS and Merck, announced that the companies have significantly broadened their existing distribution and logistics agreement...
28 June 2011 | By GlaxoSmithKline
External researchers have begun work in the GlaxoSmithKline ‘open lab’ in Spain...
28 June 2011 | By Gilead Sciences, Inc.
Development and commercialization of a new fixed-dose antiretroviral combination product...
Thermo Fisher Scientific Inc., the world leader in serving science, today announced a breakthrough workflow to overcome key analytical and informatics challenges in metabolomics.
27 June 2011 | By Novo Nordisk
Ultra-long-acting insulin degludec, lowers blood glucose levels with significantly reduced rates of hypoglycaemia (low blood sugar)...
27 June 2011 | By Sanofi
Sanofi announced the appointment of Peter Guenter, as Senior Vice President, Europe, effective July 15, 2011...
27 June 2011 | By AstraZeneca
Results from an exploratory 78-week study...
27 June 2011 | By Amgen
Amgen announced the submission of a supplemental Biologics License Application to the U.S. FDA to expand the indication for XGEVA® (denosumab)...
